BioCity's Groundbreaking SC0062 Therapy Recognized in China for Treating Diabetic Kidney Disease BioCity's SC0062, a selective endothelin A antagonist, has received Breakthrough Therapy Designation in China for diabetic kidney disease. This innovative therapy shows promise in transforming treatment approaches for chronic kidney conditions.

BioCity's Groundbreaking SC0062 Therapy Recognized in China for Treating Diabetic Kidney Disease #China #Shanghai #SC0062 #BioCity #Diabetic_Kidney_Disease

BioCity's SC0062 Successfully Meets Goals in Phase 2 Trial for Diabetic Kidney Disease Treatment BioCity's SC0062, a selective ETA antagonist, has met its primary endpoint in a Phase 2 trial for diabetic kidney disease, showing efficacy and safety.

BioCity's SC0062 Successfully Meets Goals in Phase 2 Trial for Diabetic Kidney Disease Treatment #China #Shanghai #SC0062 #BioCity #DKD